Evidence & regulatory context
- Mechanism
- Biologic (recombinant human EC-SOD/SOD3 from Pichia pastoris); not a discrete ChEMBL drug; trials exist for the Cu/Zn-SOD isoform but not EC-SOD specifically
- Target
- Not recorded
- Injury models
- Other
- Reported indication
- Not recorded
- First approval
- Not recorded
- Development stage
- Not recorded
- ChEMBL record
- Not recorded
- ChEMBL max phase
- Not recorded
- Synonyms
- Not recorded
- Note
- Not recorded
Clinical trials 0
0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.
No linked human trial in this dataset.
Preclinical evidence 1
1 studies reported at therapy level; 1 evidence entries itemised.
MouseOtherCD-1FemaleAerosol inhalation10,000 units per dayDuring hyperoxic exposure
Model: Hyperoxia-induced lung injury with fraction of inspired oxygen greater than 95 per cent
Aerosolised rhEC-SOD raised day 3 survival to 95.8 per cent against 57.1 per cent in controls, 33.3 per cent with albumin and 75 per cent with copper-zinc superoxide dismutase, and reduced lung oedema and systemic oxidative stress.
Extraction: extract · Supplied extraction confidence: 0.85. Machine-extracted fields require source verification.